3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Urinary Bladder Neoplasms
2
Prostatic Neoplasms
2
Carcinoma, Transitional Cell
2
Urologic Neoplasms
1
Squamous Cell Lung Cancer
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
295
Fluorouracil
82
Oxaliplatin
81
130-nm albumin-bound paclitaxel
68
Capecitabine
60
Leucovorin
56
Albumin-Bound Paclitaxel
54
Radiotherapy
51
Irinotecan
44
Taxes
37
Cisplatin
36
Erlotinib Hydrochloride
34
Radiosurgery
33
pembrolizumab
29
Docetaxel
27
S 1 (combination)
26
Bevacizumab
23
folfirinox
22
Nivolumab
21
Magnetic Resonance Spectroscopy
17
Cyclophosphamide
17
Cetuximab
17
irinotecan sucrosofate
16
Radiation
16
Drug Therapy
15
Surgical Procedures, Operative
14
Specimen Handling
11
Biopsy
11
durvalumab
10
Paclitaxel
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pancreatic Neoplasms
×
apatorsen
×
Clear all
NCT01844817
2017-05-16
Rainier
SCRI Development Innovations, LLC
Phase 2
Completed
132 enrolled
9 charts